FDA’s Lesko Says It Could Be Time to 'Rethink' Voluntary Genomic Submission Guidelines | GenomeWeb

PHILADELPHIA, June 23 (GenomeWeb News) - With two years of experience under its belt, it may be time for the US Food and Drug Administration to "rethink" its Voluntary Genomic Submission Guidelines program, according to Larry Lesko, director of the Office of Clinical Pharmacology at FDA's Center for Drug Evaluation and Research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.